1. Product advantages
High purity, all above 98.5%, no impurities after dissolution
We will test each batch to ensure quality
OEM and private brand services designed for free
Various cap colors available
We can also provide MT1 peptide powder
2. Factory advantages
Professional research team
More than 5 doctors in high-tech R&D laboratories
More than 1000 m2 of factory production line to ensure stable supply
More than 1200 factories to manufacture products and control quality
3. Service advantages
24-hour online service
Track package information and update it for customers
Professional sales team
Accept small order service
Redelivery service if detained by customs

Description: Tideglusib is an irreversible GSK-3 inhibitor that inhibits GSK-3 β WT and GSK-3 β The IC50 of C199A is 5 nM and 60 nM respectively.
Related categories
Signal pathway>>PI3K/Akt/mTOR signal pathway>>GSK-3
Signal Pathways>>Stem Cells and Wnt Pathways>>GSK-3
Research Fields>>Neurological Diseases
Target point
GSK-3 β (WT): 5 nM (IC50)
GSK-3 β (C199A): 60 nM (IC50)
In vitro study Tideglusib (NP12) is a small heterocyclic thiazolidinedione (TDZD) derivative, a non competitive GSK-3 β Inhibitors, IC50 values within the micro molar range [2]. Complete elimination of TNF after glutamate treatment in astrocytes and microglia cultures incubated with Tideglusib (NP031112)- α Induction of COX-2 expression. These effects of NP031112 are not caused by loss of cell viability, as 24-hour exposure of astrocytes and microglia to this TDZD does not alter cell viability [3].
In vivo study of Tideglusib (NP12) treatment and Ser-9 inhibitory phosphorylation of GSK-3 in the brain of APPsw-tauvlw mice β The average value of NP12 treatment increased by 46%, and the inactive levels of enzymes in NP12 treated mice were comparable to those found in wild-type cohorts (p=0.893) (n=6-8 for each treatment). NP12 treatment resulted in putative GSK-3 in 15-month-old mice β The phosphorylation of guided sites Ser-202 (CP13) and Ser-396/404 (PHF-1) was significantly reduced by over 60% (p=0.023 and p=0.024, respectively) [2]. Injecting Tideglusib (NP031112) (50 mg/kg) into the hippocampus of rats significantly reduced inflammation induced by kainic acid, as measured by edema formation using T2 weighted magnetic resonance imaging and glial cell activation, and had neuroprotective effects in the damaged area. Seahorse [3].
Kinase experiment will 55 μ M's [35S] Tideglusib (207 Bq/nmol) and 5 μ MGSK-3 β At 25 ℃ at 315 μ Incubate for 1 hour in 50mM Tris HCl (pH 7.5) containing 150mM NaCl and 0.1mM EGTA. Add 35 μ After incubating with the same buffer containing or without 100mM DTE, extend the incubation for an additional 30 minutes. Then process the sample in three different ways. Firstly, divide the equal portion of 125 μ L for each sample and 375 μ Mix 8M GdnHCl of L in H 2O and heat at 80 ℃ for 5 minutes. Add the second portion 125